PDCD1 and cancer: Notably, in contrast to the individual PD-1-targeted or CTLA-4-targeted mAbs, MEDI5752 was discovered to promote swift internalization and breakdown of PD-1 and to concentrate selectively in malignancies, generating stronger anti-cancer efficacy (276).